Concepedia
Statistics
Publications
6
Citations
375
H-Index
Active since
2017
Affiliations
Takeda (United States)(Current)
Takeda (United Kingdom)
National Patient Safety Foundation
Icahn School of Medicine at Mount Sinai
John Radcliffe Hospital
Aimee Blake is an author at Takeda (United States) specializing in inflammatory bowel disease, vedolizumab therapy, and pharmacotherapy.
Publications per year
2017–2019
Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease
Uma Mahadevan, Séverine Vermeire, Karen Lasch et al. · Alimentary Pharmacology & Therapeutics · 2017 · 128 citations · Full text
Medicine, Immunology, Obstetrics +15
Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
Siew C. Ng, Ida Hilmi, Aimee Blake et al. · Inflammatory Bowel Diseases · 2018 · 95 citations · Full text
Pharmacy, Infectious Diseases, Pharmacotherapy +13
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data
Russell D. Cohen, Fatima Bhayat, Aimee Blake et al. · Journal of Crohn s and Colitis · 2019 · 70 citations
Medicine, Pharmacology, Pharmacotherapy +16
Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data
Ryan C. Ungaro, Fatima Bhayat, Aimee Blake et al. · Alimentary Pharmacology & Therapeutics · 2019 · 47 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +14
Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials
Brian G. Feagan, Fatima Bhayat, Mona Khalid et al. · Journal of Crohn s and Colitis · 2018 · 25 citations · Full text
Life Sciences, Immunology, Pharmacotherapy +17
1–5 of 6